AstraZeneca Q3 Preview: Oncology Portfolio Keeps Growing
Sales of Lynparza, Tagrissa And Imfinzi Stay Strong
AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.
AstraZeneca, which analysts said had an 'exceptional' second quarter, is expected to have also kept that momentum up in the third quarter.